Last reviewed · How we verify
Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.
Allogeneic hematopoietic stem cell transplantation (HTC) is the only curative option for many patients with hematologic malignancies but \>50% of this patients will develop extensive chronic graft-versus-host disease (cGVHD), which remains the most important complication after HTC. Classically, the most effective strategies to prevent GVHD have not improved survival; therefore, the new strategies are being sought. This study is designed in two phases: the main objective for phase I study is the more suitable dose for ixazomib search. Phase II study is designed to evaluate the efficacy of ixazomib at the doses stablished in phase I.
Details
| Lead sponsor | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
|---|---|
| Phase | PHASE1, PHASE2 |
| Status | ACTIVE_NOT_RECRUITING |
| Enrolment | 142 |
| Start date | Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma
Interventions
- Ixazomib
- Tacrolimus
- Sirolimus
- Any prophylaxis for GVHD
Countries
Spain